Evidence map›Paper›PMID 39716084›Full record

Trial reportBMC pediatrics2024

Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Büşra Tetik Dinçer, Ayşe Merve Usta, Alev Kural, Nazlı Helvacı, Ahmet Uçar, Nafiye Urgancı

Erratum issued Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06229184 (Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06229184 nacompletednot on this map

Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?

TypeinterventionalSponsorSisli Hamidiye Etfal Training and Research HospitalRan2022 to 2023Enrolled41ConditionsObesity, Childhood, NAFLDArmsFecal Calprotectin Test
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Büşra Tetik DinçerDepartment of Pediatrics, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. busra.tetik@sbu.edu.tr.
Ayşe Merve UstaDepartment of Pediatrics, Division of Pediatric Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Alev KuralDepartment of Biochemistry, Bakırkoy Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Nazlı HelvacıDepartment of Biochemistry, Bakırkoy Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Ahmet UçarDepartment of Pediatrics, Division of Pediatric Endocrinology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Nafiye UrgancıDepartment of Pediatrics, Division of Pediatric Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD.

methodsBetween November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184).

resultsThe median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59-50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018).

conclusionsFC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject.

trial registrationThis trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184).

Indexed as

BiomarkersFecesLeukocyte L1 Antigen ComplexNon-alcoholic Fatty Liver DiseasePediatric ObesityAdolescentCase-Control StudiesChildFemaleHumansMaleProspective StudiesBiomarkersLeukocyte L1 Antigen ComplexAdolescentFecal calprotectinNon-alcoholic fatty liver diseaseObesity

Identifiers

PMID39716084
PMCPMC11665081

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.